Dr. Jason Alcorn covers steps 4 and 5 of the GUIDE Communication Framework, explaining how to direct the patient and carer to additional support and the importance of empowering the patient.

Watch the video and download the slides


The GUIDE Communication Framework: Strengthening shared decision-making between nmCRPC patients and the healthcare team

This is the last in a series of three newsletters explaining the GUIDE Communication Framework, a simple 5-step approach to optimise the role of the nurse in strengthening shared decision-making between nmCRPC patients and their healthcare team.

GUIDE’s five letters each represent a crucial step in your conversations with patients with prostate cancer.

  • Gain insight into goals of treatment and care
  • Understand gaps in the patient's knowledge
  • Inform and educate
  • Direct to additional support
  • Empower the patient

Dr. Jason Alcorn explains how to Direct the patient and the carer to additional support and the importance of Empowering the patient, making them feel they can actively participate in the shared decision-making and treatment process, and why these steps are an important part of a successful treatment journey.

In the first newsletter, Veerle Lamotte covered steps 1 and 2 of the GUIDE framework and explained why it’s important to Gain insight into the goals of treatment and care as a first step in supporting your patients along the agreed treatment journey and how to Understand the gaps in the patient’s knowledge, allowing you to prioritise where you focus when it comes to informing and educating the patient.

In the second newsletter, Joanie Pfahl and Jennifer Sutton covered step 3 of the GUIDE Communication Framework and explain the importance of Informing and educating the patient, and why it is essential for nurses to have up-to-date knowledge about the disease and common symptoms, key studies relating to nmCRPC, treatment aims and options, potential side effects and proactive management as addressing patients’ knowledge gaps in the right way is critical in managing their treatment successfully.

Hello, I am Dr Jason Alcorn and I'm from The Mid Yorkshire Hospitals NHS Trust in the United Kingdom.

I'm going to be talking about the strengthening shared decision-making between non-metastatic castrate-resistant prostate cancer patients and the healthcare team.

Directing the patient to additional support and Empowering the patient

This is using the GUIDE Communication Framework. I will be talking about directing to additional support and empowering the patient. If we consider the first step is directing patients to additional support, we must consider all the local options available in our areas, centres or regions.

We must consider the information provision to patients and ensuring the patient understands the information provided.

Empowering the patient by involving them in the shared decision-making process can increase the likelihood of treatment success.

As Uro-oncology nurses, we play a vital role in this process, we undertake holistic reviews of patients and ensure the patients have the right knowledge.  Factors to consider are: the physical and psycho-social aspects, such as any existing comorbidities, or barriers that the patients may face such as psychological distress of the disease.

Also understanding the treatment options of darolutamide, apalutamide and enzalutamide. These may present with potential drug interactions.  We must understand the safety profile or any polypharmacy that the patient may have and also consider bone health.

We must take into account the quality of life of the patient and also their wishes, these are paramount to involving them in their treatment and decision-making process.

To download the slides go to gunursesconnect.cor2ed.com. Thank you for listening on behalf of GU Nurses CONNECT and remember - download the slides.

Jason Alcorn is the Nurse Consultant for Uro-oncology and Andrology at the Mid Yorkshire Hospitals NHS Trust.  He has worked at the Trust for 20 years. The Mid Yorkshire Hospitals NHS Trust is a specialist cancer centre for urological cancers. Jason started in the nursing profession after a career in the military.  After completing a Bachelor’s degree developing student nurse resources, he then studied for a Master’s degree seeking to understand registered nurse understanding of delegation to healthcare assistants.  This led to him being a fellow of the higher education academy and a registered teacher.  He then studied for a professional doctorate seeking to understand why patients withdraw early from Bacillus Calmette-Guerin treatment for urothelial cancer. Jason has presented at several national and international conferences, as well as running workshops locally and in the Middle East on behalf of EAUN, and he has also published several articles from his research activity.  He is an active board member of the European Association of Urological Nurses (EAUN) and his responsibilities on the board include education, accreditation and endorsement. __________________________

Programme summary
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

A novel therapeutic framework 

Experts
Dr Komal Jhaveri, Oncology Brothers (Moderators)
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
patient-support Patient Support

Episode

2

of 2

episode
Oncology Endocrinology Rare diseases 
Thriving beyond an EP-NEC diagnosis

Perspectives on treatment and care 

Experts
Jessica Thomas
Endorsed by
NET-Research-Foundation Minkhas mission
  • clock 4 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
patient-support Patient Support

Episode

1

of 2

episode
Oncology Endocrinology Rare diseases 
Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC)

Insights for patients and care partners 

Experts
Meredith Cummins
Endorsed by
INCA
NeuroEndocrine Cancer Australia Neuroendocrine Cancer Foundation NET-Research-Foundation
Neuroendocrine Cancer UK Minkhas mission
  • clock 5 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
eks
EKS / On-demand webinar
Oncology 
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice

On-demand materials from an Experts Knowledge Share event

Experts
Dr Elizabeth Smyth, Prof. Aziz Zaanan, Prof. Markus Moehler
Endorsed by
ESDO
Digestive Cancers Europe
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 67 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Amgen.